drugset / Trial / NCT01196676

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

NCT01196676 ↗

Phase 1 Completed 63 enrolled AstraZeneca
RandomizedSingle-groupQuadruple-blind

Summary

This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.

Timeline

Start
2010-08
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4451 Unknown 1 mg Oral
Subject AZD4451 Unknown 5 mg Oral
Subject AZD4451 Unknown 25 mg Oral

Indications